NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Catalyst Pharmaceuticals Inc (CPRX) Stock Analysis

Catalyst Pharmaceuticals Inc (CPRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CPRX

$31.49

$0.00 (0.00%)

Last trade July 21, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CPRX with… →

CPRX Key Statistics

As of Jul 21, 2026
Trading
Open
$31.49
Previous Close
$31.49
52-Week Range
19.05–32.56
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.74
Valuation
Market Cap
$3.85B
P/E Ratio
18.20
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.05
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.46
EPS (ttm)Profit attributable to each share over the last twelve months.
1.73
Financials (FY)
Revenue (FY)
$588.99M+19.78%
Net Income (FY)
$214.33M+30.78%
Profit marginThe share of revenue left as profit after all costs and taxes.
37.08%
1-Year Return
+49.88%
Dividend and dates
Avg Volume
2.54M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CPRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+34.92%
2025+11.84%
2024 (partial year)−2.75%

As of July 21, 2026.

CPRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$588.99M$214.33M36.4%
2024$491.73M$163.89M33.3%
2023$398.20M$71.41M17.9%
2022$214.20M$83.08M38.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$588.99M$501.74M$257.78M$214.33M36.4%
2024$491.73M$422.89M$195.12M$163.89M33.3%
2023$398.20M$346.24M$86.81M$71.41M17.9%
2022$214.20M$179.81M$101.84M$83.08M38.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CPRX Valuation vs Biotechnology Median

Median of 656 stocks
MetricCPRXBiotechnology medianvs median
P/E18.2012.5745% above
P/S ratio6.4615.2658% below
Profit margin37.08%0.00%37.1 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Catalyst Pharmaceuticals Inc (CPRX) carries a market capitalisation of $3.85B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 182 employees.

Over the past 52 weeks the price has ranged from $19.05 to $32.56. CPRX last closed at $31.49 on July 21, 2026. The close was unchanged from the previous session. The latest close sits 65.3% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $588.99M. Against the prior fiscal year total of $491.73M, that is a change of +19.78%. Net income for the same year was $214.33M. That is +30.78% against the prior fiscal year. The reported profit margin is 37.08%. That is 37.1 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 1.73.

Across the 4 fiscal years on file, revenue moves from $214.20M in 2022 to $588.99M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 18.2. That is 44.79% above the Biotechnology median of 12.57. The forward P/E on file is 9.05. The price-to-sales ratio is 6.46. On price-to-sales that is 57.69% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 0.74. Daily returns over the trailing 1 year annualize to a volatility of 31.91%. Over the trailing twelve months the price has returned +49.88%. The stored price history starts on December 19, 2024, and the total return since then is +46.74%.

Growth & Income

The record shows no dividend for CPRX.

So far in 2026 the price is +34.92%. The record holds one complete calendar year, 2025, which returned +11.84%.

Peer Comparison

Catalyst Pharmaceuticals Inc (CPRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Catalyst Pharmaceuticals Inc CPRX $3.85B 18.2
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Catalyst Pharmaceuticals Inc trades at a P/E of 18.2.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of July 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Visit website →